Evidence map›Paper›PMID 41526513›Full record

ReviewNature biotechnology2026

Targeted delivery of genome editors in vivo.

Wayne Ngo, Jamie L Y Wu, Kevin M Wasko, Jennifer A Doudna

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Adeno-Associated Viral Vector (AAV)-Mediated In Vivo CRISPR-Cas9 Delivery.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. Clinical translation of epigenome editing technologies.Current opinion in biomedical engineering · 2026
    Article
  3. Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wayne NgoInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-5755-2303
Jamie L Y WuInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Kevin M WaskoInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Jennifer A DoudnaInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA. doudna@berkeley.edu.ORCID http://orcid.org/0000-0001-9161-999X

Funding

Targeted Delivery of Cas9 to Lung Epithelial Cells using Enveloped Delivery VehiclesR21HL173710 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI DOUDNA, JENNIFER A · 2024 to 2025
$520k
DOE | LDRD | Lawrence Livermore National Laboratory (LLNL) DE-AC52-07NA27344Howard Hughes Medical InstituteNHLBI NIH HHS R21 HL173710
6 · The paper itself

Abstract

Genome editing has revolutionized the treatment of genetic diseases, yet the difficulty of tissue-specific delivery currently limits applications of editing technology. In this Review, we discuss preclinical and clinical advances in delivering genome editors with both established and emerging delivery mechanisms. Targeted delivery promises to considerably expand the therapeutic applicability of genome editing, moving closer to the ideal of a precise 'magic bullet' that safely and effectively treats diverse genetic disorders.

Indexed as

Gene EditingGenetic TherapyGene Transfer TechniquesAnimalsCRISPR-Cas SystemsHumans

Identifiers

PMID41526513
PMCPMC12875382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.